Amgen Signs Billion-Dollar Deal to Acquire BioVex for its Oncolytic Vaccine
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 2 (Table of Contents)
Published: 7 Feb-2011
DOI: 10.3833/pdr.v2011.i2.1430 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Amgen has further demonstrated its commitment to oncology by acquiring the biological vaccine developer BioVex for up to US$1 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS